News | October 14, 2007

Cardiovascular Risk Related to Breast Cancer Treatment

October 15, 2007 - Oncologists need to consider the affects on the cardiovascular system when treating early breast cancer, according to a review article in the Oct. 9 issue of the Journal of the American College of Cardiology.

The "multiple hits" on heart health from both breast cancer treatment and post-diagnosis lifestyle changes necessitate need more aggressive cardiovascular risk management, said Lee W. Jones, Ph.D., Duke University Medical Center, and his team of researchers.

Although only indirect evidence supports this additional risk, the consequences are likely to become increasingly important for oncologists and cardiologists treating these women, researchers said.

"While we may achieve what amounts to miracle cures and have stupendous success, that comes, at times, with a price," said coauthor Pamela S. Douglas, M.D., also of Duke.

Further research is needed before making a universal risk management recommendation for women with breast cancer, the researchers said. But they suggested making a formal cardiovascular risk assessment with Framingham or Reynolds risk scores at baseline before adjuvant therapy.

"Consideration should be given to more aggressive management of risk factors than might otherwise be indicated, in view of the 'multiple-hit' hypothesis presented here," they said.

They added, "All women should be counseled about the value of a healthy lifestyle, and a program of individualized primary prevention should be undertaken as described in the American Heart Association guidelines." Ideally this should be before beginning adjuvant breast cancer treatment.

The researchers noted that many of these women are already at risk for cardiovascular disease. Studies have shown 62 percent of breast cancer patients are either overweight or obese and 36 percent are sedentary.

Then, after diagnosis, women typically decrease their physical activity by two hours a week with even greater reductions for those who receive multimodal breast cancer treatment, the investigators said. And, more than 70 percent of breast cancer patients gain 5.5 to 13.7 pounds during adjuvant therapy.

Direct and indirect effects of breast cancer treatment then add to this risk, the researchers said.

Anthracycline-based chemotherapy has gotten the lion's share of attention for decreased left ventricular ejection fraction leading to heart failure, but "virtually all adjuvant therapies are associated with unique and varying degrees of cardiovascular injury," they said.

Modern radiation techniques have been associated with cardiac perfusion defects in 50 percent to 63 percent of women in prospective studies.

Tamoxifen increases the occurrence of thromboembolic events. Decreases in serum estrogen with aromatase inhibitors have raised concern over adverse cardiovascular effects, although longer-term follow-up with this class of drugs is needed to determine the full impact on heart health, the researchers said.

Trastuzumab (Herceptin) also has relatively short follow-up for cardiovascular effects in clinical trials, but already a 2.0 percent to 4.1 percent heart failure occurrence rate and 3.0 percent to 18.0 percent occurrence rate of asymptomatic cardiac dysfunction have been reported.

Angiogenesis inhibitors bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent), and investigational vascular disrupting agents are already associated with cardiovascular complications, including hypertension, arterial thromboembolic events, cardiac troponin increases, and left ventricular ejection fraction reductions.

Pre-existing heart disease risk factors may also increase the likelihood of breast cancer treatment-related cardiovascular complications, the researcher said.

Overall, breast cancer patients' cardiovascular risk profiles after primary therapy were worse than age- and gender-matched controls in two pilot studies by Dr. Jones' group, "supporting our contention of the 'multiple hit.'"

"Thus, as women progress through the selected treatment regimens, they will be subjected to a series of sequential or concurrent cardiovascular insults coupled with lifestyle perturbations that collectively leave patients with overt or sub-clinical cardiovascular disease," they said.

"At a minimum, these insults enhance susceptibility to further cardiovascular injury and, ultimately, risk of premature cardiovascular disease mortality," they concluded.

The consequences of multiple cardiovascular hits are likely to become increasingly important in early breast cancer management, the researchers said.

"Overall, this information is of critical importance to cardiovascular physicians who will increasingly be called upon to evaluate and treat these women," Dr. Jones and colleagues said.

The authors provided no information on conflicts of interest.
Source: Journal of the American College of Cardiology
Source reference:
Jones LW, et al "Early Breast Cancer Therapy and Cardiovascular Injury" J. Am Coll Cardiol 2007; 50: 1435-41.

For more information: www.acc.org

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Overlay Init